Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from China Medical System Holdings ( (HK:0867) ).
China Medical System Holdings Limited has signed a 20-year agreement with Alpha Cognition Inc. to exclusively develop and distribute ZUNVEYL, a new drug for treating mild-to-moderate Alzheimer’s dementia, across Asia (excluding Japan), Australia, and New Zealand. This collaboration positions the company to address the growing demand for Alzheimer’s therapies in these regions, particularly with ZUNVEYL’s potential to offer effective treatment with fewer side effects, thereby enhancing patient compliance and safety.
More about China Medical System Holdings
China Medical System Holdings Limited operates within the pharmaceutical industry, focusing on the development, registration, manufacturing, and commercialization of medical products, particularly in Asia, Australia, and New Zealand. The company has entered into a strategic agreement to expand its portfolio in the neurodegenerative disease treatment sector.
YTD Price Performance: -1.58%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.22B
For a thorough assessment of 0867 stock, go to TipRanks’ Stock Analysis page.